IN THE UNITED STATES DISTRICT COURT FOR THE

NORTHERN DISTRICT OF ILLINOIS

EASTERN DIVISION

COLONY CAPITAL LLC, )

derivatively on behalf of PSYBIO )

THERAPEUTICS, INC., )

)

Plaintiff, )

)

v. )

) No. 20 cv 3885

EVAN LEVINE, ROSS CARMEL, ROBERT ) Judge Charles R. Norgle, Sr. 

NATHAN and CARMEL, MILAZZO )

& DICHIARA f/k/a CARMEL, MILAZZO & )

FEIL, )

)

Defendants. )

)

VERIFIED AMENDED COMPLAINT

Colony Capital LLC, derivatively on behalf of Psybio Therapeutics, Inc., by and 

through its attorneys, Howard L. Teplinsky, Katherine A. Grosh, and Roenan Patt of LEVIN 

GINSBURG states the following as its Verified Amended Complaint against Evan Levine, 

Ross Carmel, Robert Nathan and Carmel, Milazzo & Feil, LLP, f/k/a Carmel, Milazzo & 

DiChiara:

ALLEGATIONS COMMON TO ALL COUNTS

1. This is an action to redress the systematic oppression and blatant breaches of 

fiduciary duty owed to a minority shareholder of a company that he founded by the company’s 

other shareholders, officers and directors. Through a series of illegal and improper “meetings” 

held under cover of darkness and without Colony Capital LLC’s knowledge or consent, the 

Defendants improperly diluted or eliminated Colony Capital LLC’s substantial equity interest in 

Psybio Therapeutics, Inc., allegedly terminated its member and manager, Richard Corbin’s 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 1 of 17 PageID #:186
2

(“Corbin”) employment as Chief Financial Officer, and attempted to strip Corbin of his status as 

a director. Defendants’ conduct, including the filing of a frivolous lawsuit unsuccessfully 

seeking prior restraint of Corbin’s speech and other temporary and preliminary injunctive relief, 

and placing the company’s most important contract in jeopardy, has caused substantial injury to 

Psybio Therapeutics, Inc. Defendants’ conduct was motivated by self-dealing and was not 

related to any legitimate business purpose.

THE PARTIES

2. Plaintiff Colony Capital LLC is a citizen of the State of Illinois, as all of its 

members are individuals who reside and are domiciled in the State of Illinois. 

3. Defendant Ross Carmel is a citizen of the State of New York. On information 

and belief, he resides and is domiciled in the State of New York. 

4. Defendant Robert Nathan is a citizen of the State of New York. On information 

and belief, he resides and is domiciled in the State of New York. 

5. Defendant Carmel, Milazzo & Feil LLP, f/k/a Carmel, Milazzo & DiChiara

(“CMD”) is a partnership. Each of its partners, Ross Carmel, Chris Milazzo, Timothy Feil and 

Peter DiChiara are citizens of the State of New York and they reside and are domiciled in the 

State of New York. 

6. Defendant Evan Levine is a citizen of the State of California. Levine resides in 

and is domiciled in the State of California. 

JURISDICTION AND VENUE

7. This Court has subject matter jurisdiction over the claims asserted herein 

pursuant to 28 U.S.C. 1332 in that Plaintiff and Defendants are citizens of different states 

and the amount in controversy, exclusive of costs and interest, exceeds $75,000. 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 2 of 17 PageID #:187
3

8. Venue is proper in this judicial district pursuant to 28 U.S.C. § 1391(b)(2) 

because a substantial part of the events giving rise to the claims asserted herein occurred in 

thisDistrict. 

9. Plaintiff Colony Capital LLC is the owner of approximately one-third of the 

issued shares of PsyBio Therapeutics, Inc. (“PsyBio”), a Delaware corporation. Corbin is a 

manager and member of Colony Capital LLC, and was the sole incorporator of PsyBio. At all 

relevant times, Corbin was and is a director and an officer of PsyBio. 

10. PsyBio is in the business of supporting the research and development of medical 

uses for psilocybin to treat emotional and mental conditions. Corbin became involved in the 

industry in or about February of 2019 when Defendant Evan Levine (“Levine”), Corbin’s thenformer business associate, asked Corbin if he was interested in locating assets through which 

they could develop a company. Corbin was charged with locating individuals and universities 

that were conducting research in the medical uses of psilocybin and evaluating whether the 

researchers would be a good fit through which to develop the business. 

11. In September of 2019, Corbin identified and contacted Professor Andrew Jones at 

the Miami University in Oxford, Ohio (“Miami University”) to determine whether research that 

he was performing on the health effects of psilocybin would a be a good platform for PsyBio’s 

business. 

12. Along with Levine, on November 21, 2019, Corbin went to Oxford, Ohio and 

personally met with Professor Jones to discuss a possible role for both the university and for him 

personally. Levine and Corbin again visited Miami University and Professor Jones on December 

18 and December 19, 2019. The purpose of their meeting was to discuss entering into a venture 

together which would include the funding of Professor Jones’s research. 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 3 of 17 PageID #:188
4

13. Although PsyBio had yet to take steps to incorporate, on January 15, 2020, the 

law firm of Carmel, Milazzo & Dichiara (“CMD”), through its partner Ross Carmel (”Carmel”), 

entered into a “Retainer for Legal Representation” agreement. CMD agreed to represent PsyBio 

in connection with the formation and structure of the company, drafting employment agreements 

for Levine and Corbin, reviewing a license agreement between PsyBio and Miami University, 

preparation of the offering materials for PsyBio’s first two rounds of financing, and all general 

corporate matters through the second round of financing. In exchange, CMD, through Mr. 

Carmel, received 4% of the company’s common stock. A true and correct copy of the Retainer 

Agreement is attached hereto as Exhibit A. 

14. Following PsyBio’s retention of CMD in exchange for 4% of the company’s 

stock, Corbin incorporated PsyBio on January 21, 2020 by filing a Certificate of Incorporation 

with the Delaware Secretary of State. Thereafter, on January 31, 2020, as sole incorporator of 

PsyBio, Corbin adopted a resolution appointing Levine, attorney Ross Carmel and himself as 

initial directors. A true and correct copy of the 1/31/20 Action by Written Consent of the Sole 

Incorporator of PsyBio Therapeutics, Inc. is attached hereto as Exhibit B. 

15. On February 7, 2020, Levine, Carmel and Corbin, as the members of the Board of 

Directors, elected the company’s officers. Levine was elected Chief Executive Officer and 

President. Corbin was elected Treasurer/Chief Financial Officer and Secretary. Also on that day, 

the company authorized the issuance of 60,000,000 shares of stock with a par value $0.001 per 

share. The initial shareholders were: a) Levance Prospects LLC, a company controlled by 

Levine, holding 10,000,000 shares, and b) Robert S. Nathan holding 10,000,000 shares. 

Additionally, 10,000,000 shares were issued to Colony Capital LLC, a company that Corbin 

controls and, consistent with the Retainer Agreement, 1,200,000 shares were issued to the 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 4 of 17 PageID #:189
5

company’s attorneys, CMD. On February 7, 2020, the company also adopted and ratified its 

Bylaws. A true and correct copy of the Action by Unanimous Written Consent with Bylaws

attached is attached hereto as Exhibit C. 

16. CMD did not draft employment agreements for Corbin or Levine, if at all, until 

sometime after May 6, 2020. 

The Letter of Intent with Miami University 

17. Negotiations with Miami University and Professor Jones culminated in a signed 

Letter of Intent dated February 24, 2020. A true and correct copy of the Letter of Intent is 

attached hereto as Exhibit D. 

18. The purpose of the non-binding Letter of Intent was to “summarize the essential 

terms and conditions under which” Miami University Professor Jones and PsyBio intended to 

work together to advance and expand the university’s research. The Letter of Intent contemplated 

that the parties would enter into a sponsored research agreement and exclusive license agreement 

to license the provisional patent application for the Methods of Production of Psilocybin and all 

intellectual property developed in the pursuit. The Letter of Intent contemplated that Professor 

Jones would receive 13% of PsyBio’s stock, as well as an annual research fee and a fee for 

serving as Chairman of PsyBio’s “Scientific Advisory Board.” The letter of Intent also 

contemplated that Miami University and Professor Jones would split 50% of the company’s net 

revenues (4% of sales) representing the royalties the University shared with Dr. Jones. Corbin 

believed that under the agreement that he helped negotiate, the company, the university and 

Professor Jones would benefit. 

The Company Seeks Investors

19. On or about April 27, 2020, Levine sent to Corbin a draft letter outlining the 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 5 of 17 PageID #:190
6

terms under which Grandhill Capital, Inc., a private equity firm based in Toronto, Canada, would 

become an investor in PsyBio.

20. When Corbin received the draft term sheet, he was very upset and believed that if 

the company entered into a deal with Grandhill Capital, it would be at great risk of breaching its 

agreements with Miami University. 

21. The deal that Levine was negotiating with Grandhill Capital involved the 

following:

a. Grandhill would cause PsyBio to acquire a publicly traded “shell” corporation in 

order to take PsyBio public without having to comply with the requirements of 

an IPO; 

b. Grandhill would loan $500,000 to PsyBio, the proceeds of which would be held 

in escrow by CMD; 

 

c. The “shell” company created by Grandhill would effectively receive 12.5% of 

PsyBio’s shares;

d. Grandhill would attempt to raise additional equity in the amount of $1.4 million; 

e. Grandhill would have the right to replace Corbin as CFO with a Vice President 

of Finance, all paid for by PsyBio;

f. PsyBio would be required to pay Grandhill monthly rent for an office location in 

Canada despite the fact that it was operating out of the United States; 

g. PsyBio would be required to issue to Grandhill 10% of the PsyBio’s equity, or 

approximately 4,644,444 shares of common stock, for “nominal consideration”; 

and 

h. For the opportunity to borrow money from Grandhill, replace Corbin as CFO, 

pay a new CFO, pay rent for space it did not need, and give up 32.5% of the 

company, PsyBio would pay Grandhill an additional $5,000 per month for one 

year. 

22. The proposed deal with Grandhill would have materially and detrimentally 

affected PsyBio’s finances. For the $500,000 loan it was proposing to make to PsyBio, 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 6 of 17 PageID #:191
7

Grandhill would receive nearly one-third of the company’s stock through the acquisition of 

“extra shares” and “advisory shares” -- an amount that was multiple times the value of 

Grandhill’s actual investment.

23. Entering into the deal with Grandhill would likely have put PsyBio’s ability to 

live up to its commitments to the Miami University in jeopardy. Corbin’s belief was that under 

the Grandhill deal, there would not be sufficient cash to fund Miami University’s research 

efforts, despite PsyBio’s commitments to the contrary. 

Corbin Objects to the Grandhill Deal

24. On or about April 27, 2020, as was his right to do as an officer, director and 

shareholder (through Colony Capital LLC), Corbin voiced his strong objection to Levine 

regarding the contemplated transaction with Grandhill. In addition, Grandhill’s eventual 

takeover of PsyBio, including Corbin’s immediate replacement as CFO, caused him concern 

because none of PsyBio’s employees and officers had employment agreements with PsyBio. 

Accordingly, on April 27, 2020, Corbin sent an email to Evan Levine stating, “we need 

employment agreements too before any deal. Even with no cash, something to secure long term 

scenarios.” Corbin was proposing that each of the officers and employees, including Levine and 

Nathan, receive an employment agreement before finalizing any deal with Grandhill. A true and 

correct copy of Corbin’s April 27, 2020 email to Levine is attached hereto as Exhibit E.

The Proposed Employment Agreement

25. On April 27, 2020, Corbin sent Levine an email advising Levine that “we all” 

needed employment contracts prior to engaging in the Grandhill deal. Because Carmel and his 

law firm had failed to draft employment agreements, Corbin drafted and proposed an 

employment agreement for consideration and emailed it to Levine on April 30, 2020. The draft 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 7 of 17 PageID #:192
8

employment agreement proposed, in pertinent part, that: (a) Corbin’s salary would be 80% of 

Levine’s; (b) either party could terminate the agreement upon 30 days written notice; and (c) in 

the event of termination, Corbin would be entitled to a severance payment of $100,000. A true 

and correct copy of the draft employment agreement is attached hereto as Exhibit F. 

26. Based upon the proposed transaction with Grandhill, there was a likelihood that 

PsyBio would not be able to keep its commitments to Miami University, and the shareholders’ 

equity in PsyBio would be substantially diluted and Corbin would be replaced as an officer, all in 

exchange for the privilege of borrowing $500,000 from Grandhill. A true and correct copy of 

Grandhill’s executed term sheet dated April 30, 2020 is attached hereto as Exhibit G. 

27. Corbin communicated his objections to the Grandhill deal to Levine. In apparent 

response, on April 30, 2020, Corbin received a telephone call from Levine telling him for the 

first time that “Rob Nathan and Ross Carmel” were “not happy with [Corbin’s] equity 

percentage” and that Corbin’s equity in PsyBio needed to be reduced and diluted. Corbin 

objected to Levine’s suggestion that he reduce his ownership, explaining to Levine that he had 

co-founded the company and had found and originated the deal with Miami University. Corbin 

further told Levine that that because he had been working on the project since February of 2019, 

he would not agree to reduce his ownership in PsyBio.

PsyBio’s Purported Dissolution

28. In response, on or about May 1, 2020, Levine sent Corbin an email advising that 

Levine was going to seek PsyBio’s dissolution. Corbin believed that Levine’s stated intention of 

dissolving the company was merely intended to misappropriate PsyBio’s assets, destroy the 

value of PsyBio and, instead, convey them to a new company—a company in which Corbin did 

not have any ownership interest. 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 8 of 17 PageID #:193
9

29. That same day, May 1, 2020, due to the suspicious nature Levine’s representation 

regarding PsyBio’s dissolution, Corbin performed a Delaware LLC search using the term 

“PSYBIO.” The search revealed that a newly-formed entity, “PsyBio Life Sciences,” had been 

incorporated. The incorporation of PsyBio Life Sciences demonstrated to Corbin that Levine and 

Carmel were no longer acting on behalf of the interests of PsyBio and Miami University, but 

rather, were acting in their own self-interests. 

30. On May 1, 2020, in furtherance of PsyBio’s business and as part of his 

responsibilities as an officer and director, Corbin contacted Professor Jones to advise him that 

PsyBio was about to enter into a transaction with a private equity firm that caused him 

substantial concern over PsyBio’s ability to fund Professor Jones’s research efforts and that 

PsyBio’s directors were meeting to discuss the company’s possible dissolution. 

The May 4, 2020 Meeting of the Board of Directors 

31. As a direct result of Corbin: a) expressing his concern with the Grandhill 

transaction; and b) contacting Professor Jones, on May 1, 2020, Levine sent Corbin an email on 

May 1, 2020, on which Carmel was copied, directing Corbin to “be available for a meeting of the 

Board of Directors of PsyBio Therapeutics Inc.” on Monday, May 4, 2020 at 3:30 p.m. EST 

where the directors would be voting on “the dissolution of PsyBio Therapeutics Inc. and any 

other item that a Director chooses to discuss.” A true and correct copy of the May 1, 2020 email 

is attached hereto as Exhibit H. 

32. A telephonic meeting of the Board of Directors was held on May 4, 2020 where, 

despite Corbin’s dissent and without any stated business purpose, Levine and Carmel, two of the 

three directors, voted to dissolve PsyBio. During the meeting, Carmel, the company’s attorney, 

director and fellow shareholder, told Corbin that unless he agreed to reduce his equity, he “could 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 9 of 17 PageID #:194
10

have a little of something valuable or nothing,” meaning that unless Corbin voluntarily agreed to 

substantially reduce his equity in PsyBio, the remaining directors and shareholders would ensure 

that the company’s value was reduced to zero. Corbin reiterated his position that he would not 

reduce his equity in the company. Thereafter, consistent with Carmel’s threat, Levine 

immediately called a vote of directors to dissolve the company, which passed 2-1. 

33. Soon thereafter, Corbin sent a request to Carmel for a full copy of the minutes 

reflecting the Board of Director’s decision to dissolve the Company. Carmel refused to tender 

the minutes. Thereafter, in his role as secretary of PsyBio, Corbin sent an email to Ross Carmel 

with proposed minutes reflecting the actions voted on at the director’s meeting.

34. Carmel, the corporate attorney, partner of a shareholder and fellow board 

member, responded to Corbin’s email, accusing him of changing “the [email] passwords for 

PsyBio officers and advisers” and threatening Corbin that his conduct constituted tortious 

interference “as well as a multitude of derivative claims.” Furthermore, Carmel’s 

communications with Corbin demonstrated to Corbin that not only was Carmel no longer acting 

in the best interest in PsyBio as a board member or as its counsel, but was acting in his and his 

law firm’s self-interests. A true and correct copy of the May 4, 2020 email exchange is attached 

hereto as Exhibit I. 

35. In response to Carmel’s accusations, also on May 4, 2020, Corbin advised Carmel 

that he had not been told that anyone was having difficulty accessing the dissolved company’s 

email, but that he would reset people’s passwords if needed. Carmel did not respond to Corbin’s 

offer to reset the passwords. Instead, attorney Carmel responded by stating, “Once again, you 

are completely lost. You forced yourself out by providing no value and refusing to work. Please 

keep all emails and the meta data will evidence your wrongful acts and numerous privacy 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 10 of 17 PageID #:195
11

violations.” 

36. Despite Carmel’s threatening tone and language, Corbin again told Carmel that he 

needed to know which parties required a password reset so that he could perform a password 

reset. Specifically, Corbin reminded Carmel that he had failed “to state which parties need a 

password reset.” Carmel’s response was again to ignore Corbin’s request that he identify those 

people who could not access their emails so he could reset their passwords. Instead, Carmel 

again warned Corbin of “spoliation,” advising him that “there are serious consequences” for 

doing so. Instead of providing Corbin with the information so he could make sure that all 

affected persons could access their emails, Mr. Carmel continued his threats. 

37. On May 6, 2020, Levine and Carmel both advised Corbin that the May 4, 2020 

dissolution vote was “not effective” because, according to them, the directors could not vote to 

dissolve the company. Thus, based upon Levine and Carmel’s communications with Corbin on 

May 6, 2020, the May 4, 2020 board meeting to vote on “The dissolution of PsyBio 

Therapeutics” was by all appearances a calculated ruse by the other board members and the 

corporate attorney to force Corbin to accept their terms and reduce his equity. 

38. Also on May 6, 2020, with no prior notice to Corbin, Levin, Nathan and Carmel 

executed shareholder written consents purporting to remove Corbin as a board member

(collectively, “May 6 Written Consents”). True and correct copies of the May 6 Written 

Consents are attached hereto as Exhibit J. Also on May 6, 2020, Levine sent Corbin a letter 

supposedly terminating him from his corporate officer positions. A true and correct copy of the 

Termination Letter is attached hereto as Exhibit K.

39. As more fully set forth in Corbin’s Counterclaims in Psybio Therapeutics, Inc. v. 

Richard Corbin, No. 20-cv-3340 (N.D. Ill. 2020), the allegations of which are incorporated 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 11 of 17 PageID #:196
12

herein by reference, Corbin’s removal as a board member and termination as an officer was done 

contrary to the bylaws and the DCGL and done without proper notice. Further, prior to May 6, 

2020, Corbin was never told by anyone that his job performance was not acceptable or that he 

had not been doing his job. Rather, Corbin was being eliminated from PsyBio to expand the 

other equity positions of the other board members because Corbin would not agree to voluntarily 

dilute his ownership of PsyBio, and because of his legitimate concerns regarding and opposition 

to the Grandhill deal. 

 The May 21, 2020 Meeting of Officers

40. On May 21, 2020 at 3:04 p.m., because Corbin was still an officer of PsyBio, 

Corbin called an emergency meeting of PsyBio’s officers for 9:00 p.m. CST. A true and correct 

copy of the Notice for the May 21, 2020 meeting is attached hereto as Exhibit L. The purpose of 

the meeting, as stated in the notice, was to discuss Levine’s potential removal as an officer and 

various other items of business including the termination of PsyBio’s Retainer Agreement with 

CMD. 

41. At 9:00 p.m. on May 21, 2020, Corbin called in to the conference line and no one 

else appeared at the meeting. During the May 21, 2020 officers’ meeting, because the previous 

actions that Carmel and Levine had taken in attempting to dissolve the company, terminate his 

officer positions, and remove him as a director were not proper, Corbin terminated Levine as 

President, CEO and Chairman. CMD was also terminated as PsyBio’s counsel.

COUNT I

(Breach of Fiduciary Duty on Behalf of PsyBio, Derivatively, Against Levine and Carmel) 

42. Colony Capital LLC realleges and incorporates by reference the allegations 

contained in paragraphs 1 through 41 of this Amended Complaint as if fully set forth herein. 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 12 of 17 PageID #:197
13

43. As directors of PsyBio, Levine and Carmel owed fiduciary duties of care and 

loyalty, honesty and good faith to PsyBio and its shareholders, including Colony Capital LLC. 

At all relevant times, Colony Capital LLC was a shareholder at the time of the transactions 

complained of herein and remains a shareholder of PsyBio.

44. As directors, Levine and Carmel were required to act in the best interests of 

PsyBio and its shareholders and were prohibited from acting in their own self-interest to the 

detriment of PsyBio and its shareholders, including Colony Capital LLC. 

45. Because Levine and Carmel were either directly interested in or had a conflict of 

interest with respect to the improper dilution of Colony Capital LLC’s interests, their action visà-vis dissolving the company, then rescinding the dissolution, but removing Corbin from his 

positions as officer and director while at the same time establishing a new, competing entity, 

were knowing and deliberate breaches of their fiduciary duties. Levine and Carmel were acting 

in their own self-interest and were not acting in good faith or in the interests of PsyBio or the 

other shareholders. 

46. Demand by Colony Capital LLC that the board rescind the wrongful conduct or 

bring claims against Levine and Carmel would have been futile because neither Carmel nor 

Levine were disinterested.

47. If, as suspected, revenue realized through investment in and/or monetization of 

the business were diverted to Defendants’ new venture, neither Levine nor Carmel attempted to 

obtain approval from any disinterested director or shareholder. 

48. As a direct and proximate result of Levine and Carmel breaching their fiduciary 

duties by purporting to dissolve PsyBio, then reviving PsyBio, diluting Corbin’s interests, 

terminating Corbin as an officer, removing Corbin as a director and diverting PsyBio’s revenues, 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 13 of 17 PageID #:198
14

including investor capital, to a new competing entity, PsyBio was hugely devalued, with the 

losses resulting from that devaluation shouldered by the shareholders, including Colony Capital 

LLC. 

49. Carmel, Levine, Nathan and Carmel, Milazzo & Feil have benefitted by 

knowingly receiving the benefits of Carmel and Levine’s breaches of fiduciary duties, either by 

increased equity in PsyBio or as shareholders of the competing entity established by Levine and 

Carmel. 

50. This derivative action is not a collusive one to confer jurisdiction that the Court 

would otherwise lack. Any effort by Colony Capital LLC to obtain the desired action from 

Carmel and Levine would have been futile as neither Levine nor Carmel are disinterested and 

were, at all times, acting in their self-interests.

WHEREFORE, Colony Capital LLC, derivatively on behalf of PsyBio, requests 

judgment in PsyBio’s favor and against Levine and Carmel for actual damages in an amount in 

excess of $75,000 to be determined at trial, plus punitive damages in an amount to be determined 

at trial, plus interest, costs of suit and such other relief as the Court deems just and proper. 

COUNT II

(Conspiracy to Breach Fiduciary Duty on Behalf of Colony Capital LLC, derivatively, 

against Levine, Carmel, Carmel, Milazzo & Feil, and Nathan)

51. Colony Capital LLC realleges and incorporates by reference the allegations 

contained in paragraphs 1 through 50 of this Amended Complaint as if fully set forth herein.

52. There was a meeting of the minds between and among the Defendants to commit 

the wrongful acts against Corbin described herein. 

53. Defendants took action in furtherance of their conspiracy by unlawfully removing 

Corbin as an officer and director, and by improperly diluting Corbin’s ownership interest in 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 14 of 17 PageID #:199
15

PsyBio or diverting assets and corporate opportunities to a competing entity, as described herein. 

54. Carmel, Levine, Nathan and Carmel, Milazzo & Feil have benefitted by 

knowingly receiving the benefits of Carmel and Levine’s breaches of fiduciary duties, either by 

increased equity in PsyBio, control over PsyBio, or as shareholders of the competing entity 

established by Levine and Carmel. 

55. Demand by Colony Capital LLC that the board rescind the wrongful conduct or 

bring claims against Defendants herein would have been futile, because neither Carmel nor

Levine were disinterested and were, at all times, acting in their self-interests.

56. This derivative action is not a collusive one to confer jurisdiction that the Court 

would otherwise lack. 

57. The shareholders of PsyBio, including Colony Capital LLC, have been damaged 

as a direct and proximate cause of Defendants’ conduct. 

WHEREFORE, Colony Capital LLC, derivatively on behalf of PsyBio, requests 

judgment in PsyBio’s favor and against Levine, Carmel, Carmel, Milazzo & Feil, and Nathan, 

for actual damages in an amount in excess of $75,000 to be determined at trial, plus punitive 

damages in an amount to be determined at trial, plus interest, costs of suit and such other relief as 

the Court deems just and proper. 

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 15 of 17 PageID #:200
16

Respectfully submitted,

COLONY CAPITAL LLC

By: /s/ Howard L. Teplinsky

One of His Attorneys

Howard L. Teplinsky – 6197501

Katherine A. Grosh – 6277577

Roenan Patt – 6309884 

LEVIN GINSBURG

180 N. LaSalle Street, Suite 3200

Chicago, IL 60601

Tel: 312-368-0100

Fax: 312-368-0111

hteplinsky@lgattorneys.com

kgrosh@lgattorneys.com

rpatt@lgattorneys.com

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 16 of 17 PageID #:201
17

VERIFICATION

I, Richard Corbin, manager and member of Colony Capital LLC, affirm under 

penalties of perjury that the statements contained in the foregoing Amended Complaint are 

true and correct and as to such allegations made on information and belief, Corbin states that 

the verily believes them to be true. 

COLONY CAPITAL LLC

/s/ Richard Corbin

By Its: Manager and Member

Case: 1:20-cv-03885 Document #: 9 Filed: 07/23/20 Page 17 of 17 PageID #:202